BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[OncoGenex (OGXI): Biotech Targets Cancer Treatments]]>http://www.bloggingstocks.com/2011/04/06/oncogenex-ogxi-biotech-targets-cancer/http://www.bloggingstocks.com/2011/04/06/oncogenex-ogxi-biotech-targets-cancer/http://www.bloggingstocks.com/2011/04/06/oncogenex-ogxi-biotech-targets-cancer/#commentsFiled under: , ,

"OncoGenex Pharmaceuticals (OGXI) recently released their fourth quarter and year end 2010 financial results; during the conference call they discussed updates in their development programs and provided an outlook for 2011," notes biotech specialist John McCamant.

The editor of the Medical Technology Stock Letter continues, "The company reported a Q4 2010 net loss of $2.8 million or ($0.26) per share compared to Q4 2009 net profit of $3.9 million or $0.70 per share.

"OGXI finished the year in a solid position financially with $85.6 million in cash. The company expects to end 2011 with $50-$54 million on the balance sheet and use $31-$35 million in operating cash. They appear to have enough cash to fund operations into 2014.

Continue reading OncoGenex (OGXI): Biotech Targets Cancer Treatments

OncoGenex (OGXI): Biotech Targets Cancer Treatments originally appeared on BloggingStocks on Wed, 06 Apr 2011 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnology stocksBiotechnologyStocksbladder cancer treatment stocksCancerTreatmentStocksfeaturedjohn mccamantJohnMccamantlung cancer treatment stocksmedical technology stock letterOGXIOncoGenexoncology stocksprostate cancer treatment stockssteven halpernthestockadvisors.comWed, 06 Apr 2011 10:00:00 EST<![CDATA[Celgene (CELG): Cancer progress boosts biotech]]>http://www.bloggingstocks.com/2009/08/19/celgene-celg-cancer-progress-boosts-biotech/http://www.bloggingstocks.com/2009/08/19/celgene-celg-cancer-progress-boosts-biotech/http://www.bloggingstocks.com/2009/08/19/celgene-celg-cancer-progress-boosts-biotech/#commentsFiled under: , ,

"Some sectors tend to do better than others in tough times; biotechnology often surprises investors in good times and bad," suggests Brandon Clay.

In his Invest with an Edge advisory service, the growth stock advisor looks to Celgene Corporation (NASDAQ: CELG), a player in developing cancer treatments. Here's his review.

"This sometimes-perilous market niche can make or break a portfolio depending on several factors: drug pipeline, continued investment, market factors, and government approvals.

"However, despite the risks, there are times when we believe that individual biotech stocks make sense -- such as our latest recommendation for Celgene.

Continue reading Celgene (CELG): Cancer progress boosts biotech

Celgene (CELG): Cancer progress boosts biotech originally appeared on BloggingStocks on Wed, 19 Aug 2009 14:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnology stocksBiotechStocksbrandon claycancer drug stockscancer stockscancer treatment stocksCancerStocksCancerTreatmentStockscelgcelgeneinvest with an edgeInvestWithAnEdgerevlimidsteven halpernStevenHalpernthestockadvisors.comWed, 19 Aug 2009 14:00:00 EST<![CDATA[Celgene (CELG): Play offense and defense with biotech]]>http://www.bloggingstocks.com/2009/06/22/celgene-celg-play-offense-and-defense-with-biotech/http://www.bloggingstocks.com/2009/06/22/celgene-celg-play-offense-and-defense-with-biotech/http://www.bloggingstocks.com/2009/06/22/celgene-celg-play-offense-and-defense-with-biotech/#commentsFiled under: ,

"Biotech company Celgene Corp. (NASDAQ: CELG) is a prime example of a stock that plays both offense and defense," says Ian Wyatt.

In his Top Stock Insights, he explains, "The valuation is low and growth is attractive. With the pipeline of products in development, Celegene offers investors a huge upside potential."

"Celgene offers investors a steady product base, a variety of drug treatments in development and a cash pile ready to purchase existing technologies.

"Celgene engages in the discovery of therapies designed to treat cancer and immune-inflammatory related diseases. They have a number of products at the commercial stage.

Continue reading Celgene (CELG): Play offense and defense with biotech

Celgene (CELG): Play offense and defense with biotech originally appeared on BloggingStocks on Mon, 22 Jun 2009 13:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnologycancer treatment stocksCancerTreatmentStockscelgcelgenedrug development stocksDrugDevelopmentStockshealthcare stocksHealthcareStocksian wyattIanWyattimmune disease stocksImmuneDiseaseStocksstem cell researchStemCellResearchsteven halpernStevenHalpernthestockadvisors.comtop stock insightsMon, 22 Jun 2009 13:40:00 EST<![CDATA[Celgene (CELG): Selloff creates opportunity]]>http://www.bloggingstocks.com/2009/04/06/celgene-celg-selloff-creates-opportunity/http://www.bloggingstocks.com/2009/04/06/celgene-celg-selloff-creates-opportunity/http://www.bloggingstocks.com/2009/04/06/celgene-celg-selloff-creates-opportunity/#commentsFiled under: , ,

"After warning that it would only achieve the low end of its previous guidance range for 2009, Celgene (NASDAQ: CELG) sold off significantly," notes biotech expert John McCamant.

Nevertheless, in his The Medical Technology Stock Letter he sees the selloff as any opportunity, calling the company a "great growth story."

"Celgene pre-announced 1Q 09 revenues of $600 million, which was significantly below Wall Street consensus estimates of $640-$650 million.

"The earnings miss was completely unexpected, and has partially shaken the belief that the Big Bios would be able to deliver solid earnings despite the economic problems.Nevertheless, we remain positive on the CELG story.

Continue reading Celgene (CELG): Selloff creates opportunity

Celgene (CELG): Selloff creates opportunity originally appeared on BloggingStocks on Mon, 06 Apr 2009 14:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotech stocksbiotechnologyBiotechStockscancer treatment stocksCancerTreatmentStockscelgcelgenehealthcare stocksHealthcareStocksjohn mccamantJohnMccamantmedical stocksmedical technology stock letterMedicalTechnologyStockLetterpharma stockspharmaceuticalsPharmaStocksthestockadvisors.comMon, 06 Apr 2009 14:30:00 EST<![CDATA[Celgene (CELG): Strong growth in biotech]]>http://www.bloggingstocks.com/2009/02/23/celgene-celg-strong-growth-in-biotech/http://www.bloggingstocks.com/2009/02/23/celgene-celg-strong-growth-in-biotech/http://www.bloggingstocks.com/2009/02/23/celgene-celg-strong-growth-in-biotech/#commentsFiled under: ,

"Celgene (NASDAQ: CELG) reported their fourth quarter and year end numbers which showed strong revenue growth." observes biotech sector expert John McCamant.

The editor of The Medical Technology Stock Letter explains, "We remain excited about CELG's growth prospects and management's ability to deliver the goods.

"Total revenue for the quarter grew 50% to $623 million, with the primary driver being Revlimid sales of $369.4 million. Sales of their two other drugs, Thalomid and Vidaza generated $126.8 million and 69.7 million, respectively.

Continue reading Celgene (CELG): Strong growth in biotech

Celgene (CELG): Strong growth in biotech originally appeared on BloggingStocks on Mon, 23 Feb 2009 11:40:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>biotechbiotechnologycancer treatment stocksCancerTreatmentStockscelgcelgenedrug development stocksDrugDevelopmentStocksheathcare stocksHeathcareStocksjohn mccamantJohnMccamantmedical stocksmedical technology stock letterMedicalTechnologyStockLetterthestockadvisors.comMon, 23 Feb 2009 11:40:00 EST